Children's Mercy Kansas City

SHARE @ Children's Mercy
Research Days

GME Research Days 2022

May 5th, 11:30 AM - 1:30 PM

A case of an elevated tryptase
Sonya Parashar
Children's Mercy Hopital

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/researchdays
Part of the Higher Education and Teaching Commons, Medical Education Commons, Pediatrics
Commons, and the Science and Mathematics Education Commons

Parashar, Sonya, "A case of an elevated tryptase" (2022). Research Days. 5.
https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2022/ResearchDay4/5

This Poster Presentation is brought to you for free and open access by the Conferences and Events at SHARE @
Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact hlsteel@cmh.edu.

A case of an elevated tryptase (9122)
Sonya Parashar,

1Children’s

Background
autosomal dominant disorder characterized by

Symptoms

Loose stools

elevated baseline tryptase (8 ng/ml or greater)

and increased copies of α-tryptase alleles
• Occurs in 3% of the population and more
common in female patients

Case presentation
• A full term, 13-month-old female patient
presented to clinic for an elevated tryptase
• Past medical history: gastroesophageal
reflux disease
• No surgical history
• Family history: older sister with history
of flushing. She eventually had a negative
evaluation for mastocytosis
• No chronic medications

Tryptase
(ng/ml)
Other labs

Attempted
treatment

Nikita Raje,

13.0

CBC with
thrombocytosis
and eosinophilia
and peripheral
blood c-kit
D816V negative
Cetirizine as
needed +
epinephrine
autoinjector

2University

1,2
MD

Mercy Kansas City
of Missouri Kansas City
Case presentation (cont.) and evaluation
Presentation

• Hereditary Alpha Tryptasemia (HαT) is
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Management

• Diagnosis is made based on symptoms, serum tryptase
level, and genetic testing
• Treatment is supportive in nature and includes maximally
tolerated H1 and H2 histamine blockers as well as
cromolyn for gastrointestinal symptoms
• Patient with HαT and known hypersensitivity, EpiPen is
recommended.

Conclusion
• Given a higher prevalence than systematic mastocytosis,
one must have a high degree of suspicion for HαT to
include in differential diagnoses
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